insights_auto
Why is HALO down 3.13%?
Dive Deeperchevron_right
HALO:NASDAQ
Halozyme Therapeutics, Inc.
$106.94
arrow_downward
-3.13%(-3.46) 1D
$106.94
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 1, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for HALO...
Open
$109.93
High
$110.50
Low
$106.84
Mkt. cap
12.14B
Avg. vol.
2.19M
Volume
2.33M
P/E ratio
31.95
52-wk high
$116.84
52-wk low
$61.22
EPS
$3.35
Beta
0.88
Shares outstanding
113.50M
No. of employees
423
Open
$109.93
High
$110.50
Low
$106.84
Mkt. cap
12.14B
Avg. vol.
2.19M
Volume
2.33M
P/E ratio
31.95
52-wk high
$116.84
52-wk low
$61.22
EPS
$3.35
Beta
0.88
Shares outstanding
113.50M
No. of employees
423
News stories
From web sources and news partners
AD HOC NEWS
·
12 hours ago
Argus raises target for Halozyme Therapeutics stock to USD 127
Yahoo! Finance Canada
·
20 hours ago
Halozyme Therapeutics, Inc. (HALO) Stock Forecasts
Profile
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California. Wikipedia
About Halozyme Therapeutics, Inc.
CEOHelen I. Torley
Employees423
Founded1998
HeadquartersSan Diego, California, United States
SectorBiotechnology
Websitehalozyme.com